Tenax Therapeutics, Inc.
NASDAQ:TENXBiotechnology
Healthcare
$1.91 +0.88%
+$0.10 today
- Market cap
- $50.66M
- Beta
- 0.97
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$1.28
52W Low $5.34High $18.38
Volume 0.70M
Average 0.62M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$56.38M
FY 2025 · Annual
Net Income
-$52.60M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 25.15M | 5.38M | 3.23M | 12.71M | 32.67M |
| Selling, General & Admin | 7.58M | 5.68M | 5.01M | 6.79M | 23.71M |
| Operating Expenses | 32.73M | 11.05M | 8.23M | 19.49M | 56.39M |
| Depreciation & Amortization | 108.98K | 113.33K | 8K | 0 | 0 |
| EBITDA | (32.36M) | (10.93M) | (7.68M) | (17.58M) | (52.6M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (32.73M) | (11.05M) | (8.23M) | (19.49M) | (56.39M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 1.91M | 3.82M |
| Interest Expense | 949 | 4.44K | 23.97K | 23K | 0 |
| Other Income / Expenses | 253.88K | 4.75K | 523K | 1.89M | 3.79M |
| Income Before Tax | (32.47M) | (11.05M) | (7.71M) | (17.6M) | (52.6M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (32.47M) | (11.05M) | (7.71M) | (17.6M) | (52.6M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2,524.80) | (600.80) | (31.09) | (1.15) | (1.34) |
| EPS (Diluted) | (2,524.80) | (600.80) | (31.04) | (1.15) | (1.34) |
| 12.86K | 18.39K | 248K | 15.27M | 39.22M | |
| 12.86K | 18.39K | 248.45K | 15.27M | 39.22M |
TENX Earnings Waterfall · TTM
NASDAQ:TENX · Revenue to Net Income
Key Ratios
EPS$-1.41
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-7.3
P/S Ratio0.0
Analysis
$0 of revenue converted into -$57.9M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.41, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Sep 17, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 15, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 15, 2026 | |
| SC 13G/A | SC 13G/A filing | Sep 11, 2026 | |
| 8-K | Current report | Sep 9, 2026 |
How much revenue does TENX generate?
Tenax Therapeutics, Inc. (TENX) reported $0.00 of revenue in fiscal 2025.
Is TENX profitable?
Tenax Therapeutics, Inc. (TENX) reported -$52.60M of net income.
Continue the stock analysis
Jump to another research area for this company.